CY1112736T1 - Σκευασματα και μεθοδοι αντιμετωπισης της λευχαιμιας - Google Patents

Σκευασματα και μεθοδοι αντιμετωπισης της λευχαιμιας

Info

Publication number
CY1112736T1
CY1112736T1 CY20121100449T CY121100449T CY1112736T1 CY 1112736 T1 CY1112736 T1 CY 1112736T1 CY 20121100449 T CY20121100449 T CY 20121100449T CY 121100449 T CY121100449 T CY 121100449T CY 1112736 T1 CY1112736 T1 CY 1112736T1
Authority
CY
Cyprus
Prior art keywords
methods
precautions
treatment
mammal
provides methods
Prior art date
Application number
CY20121100449T
Other languages
English (en)
Inventor
Deborah A Thomas
Original Assignee
Talon Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talon Therapeutics, Inc. filed Critical Talon Therapeutics, Inc.
Publication of CY1112736T1 publication Critical patent/CY1112736T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους αντιμετώπισης των νεοπλασιών σε ένα θηλαστικό. Ειδικότερα, η εφεύρεση παρέχει μεθόδους αντιμετώπισης διαφόρων τύπων λευχαιμίας, συμπεριλαμβανομένης της οξείας λεμφοβλαστικής λευχαιμίας (ΑLL). Οι μέθοδοι αυτές περιλαμβάνουν τη χορήγηση των ενθυλακωμένων σε λιπόσωμα αλκαλοειδών της βίγκα, π.χ. βινκριστίνη, σε συνδυασμό με δεξαμεθαζόνη σε ένα θηλαστικό με λευχαιμία.
CY20121100449T 2004-08-10 2012-05-14 Σκευασματα και μεθοδοι αντιμετωπισης της λευχαιμιας CY1112736T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65148204P 2004-08-10 2004-08-10
EP05783719A EP1781255B1 (en) 2004-08-10 2005-08-09 Compositions and methods for treating leukemia

Publications (1)

Publication Number Publication Date
CY1112736T1 true CY1112736T1 (el) 2016-02-10

Family

ID=35414880

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100449T CY1112736T1 (el) 2004-08-10 2012-05-14 Σκευασματα και μεθοδοι αντιμετωπισης της λευχαιμιας

Country Status (12)

Country Link
US (2) US20090028933A1 (el)
EP (1) EP1781255B1 (el)
JP (1) JP5199666B2 (el)
AT (1) ATE545408T1 (el)
AU (1) AU2005272946B2 (el)
CA (1) CA2576222C (el)
CY (1) CY1112736T1 (el)
DK (1) DK1781255T3 (el)
ES (1) ES2382337T3 (el)
HK (1) HK1108825A1 (el)
PT (1) PT1781255E (el)
WO (1) WO2006020618A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US20120202840A1 (en) * 2009-10-09 2012-08-09 University Health Network Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases
RU2013129777A (ru) * 2010-12-08 2015-01-20 Ф. Хоффманн-Ля Рош Аг Липосомальный препарат далцетрапиба
MX2015005992A (es) 2012-11-20 2016-03-07 Spectrum Pharmaceuticals Inc Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico.
US9757385B2 (en) 2013-11-27 2017-09-12 Merck Sharp & Dohme Corp. Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
CN107073014A (zh) * 2014-05-02 2017-08-18 翁科埃斯克斯有限公司 利用噻吩并三唑并二氮杂*化合物治疗急性髓细胞白血病和/或急性淋巴细胞性白血病的方法
CN107406507A (zh) * 2015-02-12 2017-11-28 西雅图基因公司 使用cd19‑adc和长春新碱的组合疗法
ES2827523T3 (es) * 2015-03-11 2021-05-21 Riken Agente terapéutico para la leucemia intratable
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CN111658636B (zh) * 2020-06-12 2021-04-13 桂林医学院 穿心莲内酯与地塞米松联用在制备复方抗急性淋巴细胞白血病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
BRPI0009448B8 (pt) * 1999-04-01 2021-05-25 Univ Texas kit para uso no tratamento de uma neoplasia em um mamífero
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer

Also Published As

Publication number Publication date
ES2382337T3 (es) 2012-06-07
AU2005272946B2 (en) 2012-01-12
EP1781255A1 (en) 2007-05-09
JP5199666B2 (ja) 2013-05-15
JP2008509911A (ja) 2008-04-03
EP1781255B1 (en) 2012-02-15
HK1108825A1 (en) 2008-05-23
WO2006020618A1 (en) 2006-02-23
US20120164211A1 (en) 2012-06-28
DK1781255T3 (da) 2012-05-29
WO2006020618A8 (en) 2006-11-02
US20090028933A1 (en) 2009-01-29
ATE545408T1 (de) 2012-03-15
AU2005272946A1 (en) 2006-02-23
CA2576222C (en) 2014-09-30
PT1781255E (pt) 2012-05-21
CA2576222A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
CY1112736T1 (el) Σκευασματα και μεθοδοι αντιμετωπισης της λευχαιμιας
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
FR13C0062I1 (el)
PL1682126T3 (pl) Podstawione benzazole i ich zastosowanie jako inhibitorów kinazy Raf
CY1112387T1 (el) Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη
IL185288A (en) An albumin-containing paclitaxel formulation in the form of nanoparticles for use in combination with other chemotherapeutic agents for cancer
WO2004087075A3 (en) Compositions and methods for treating cancer
TW200621240A (en) Cancer treatments
PL1781296T3 (pl) Pochodne chinazolinowe i ich zastosowanie w leczeniu nadpłytkowości
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
AR053338A1 (es) Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
WO2005000211A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування
EP1585963A4 (en) METHOD FOR EVALUATING A MYELOUS SUPPRESSION STATE
CY1110114T1 (el) Προσδετης αλφα-2-δελτα για την αγωγη των συμπτωματων του κατωτερου ουροποιητικου συστηματος
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
HUP0400648A2 (hu) Ecteinascidin-743-t tartalmazó tumorellenes kezeléseknél alkalmazható készítmények
CR9200A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos
WO2006102611A3 (en) Therapeutic agents for the treatment of leukemia
UY29532A1 (es) Derivados del ácido 6,7-dihidro-5h-imidazo(1,2-a)imidazol-3-sulfónico
NO20092078L (no) Fremgangsmate for behandling av alkoholmisbruk, adiksjon og avhengighet
PL373998A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy